Praxis Precision Medicines Inc.
Praxis Precision Medicines Reports Q2 2024 Financial Results and Corporate Update
Summary
Praxis Precision Medicines, Inc. reported its financial results for the quarter ended June 30, 2024, highlighting progress in its clinical programs and a strong cash position. The company announced up to four programs in the registrational phase by 2025, with key milestones expected in the second half of 2024 and first half of 2025. Praxis also updated its corporate presentation for investor meetings, available on its website. The company's cash and investments of $434 million as of June 30, 2024, maintain a runway into 2027.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement